Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
Eur J Neurosci ; 21(3): 733-40, 2005 Feb.
Article in English | MEDLINE | ID: mdl-15733091

ABSTRACT

We reported recently that angiotensin-converting enzyme (ACE) significantly degraded amyloid beta-peptide (A beta) to inhibit aggregation and cytotoxicity of A beta in PC12h cells in vitro. On the other hand, others reported that ACE had two domains with highly homologous active centres, the N-domain and C-domain, but that they differed in their characteristics such as optimum chloride ion concentration, inhibition kinetics for various ACE inhibitors and rate of hydrolysis for many substrates. The aim of this study was to determine the specific ACE domain primarily responsible for degradation of A beta. For this purpose, a series of ACE recombinant proteins, each containing only one intact domain, was constructed and expressed in COS7. Our results showed that all ACE recombinant proteins obtained were enzymatically active in terms of angiotensin I cleavage. However, inhibition of A beta aggregation and cytotoxicity of the N-domain were higher than those of the C-domain. Reverse-phase high-performance liquid chromatography analyses confirmed that the N domain degraded A beta. Our results indicate that the N domain of ACE is primarily responsible for the degradation of A beta.


Subject(s)
Alzheimer Disease/metabolism , Amyloid beta-Peptides/metabolism , Peptide Fragments/metabolism , Peptidyl-Dipeptidase A/metabolism , Amyloid beta-Peptides/antagonists & inhibitors , Angiotensin-Converting Enzyme Inhibitors/pharmacology , Animals , Binding Sites/drug effects , COS Cells , Chlorocebus aethiops , Humans , PC12 Cells , Peptide Fragments/pharmacology , Peptidyl-Dipeptidase A/pharmacology , Rats
SELECTION OF CITATIONS
SEARCH DETAIL
...